lixiana

lixiana Uses, Dosage, Side Effects, Food Interaction and all others data.

lixiana is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy.

Administration of edoxaban results in prolongation of clotting time tests such as aPTT (activated partial thromboplastin time), PT (prothrombin time), and INR (international normalized ratio).

lixiana
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	lixiana
Availability	Prescription only
Generic	Edoxaban
Edoxaban Other Names	Edoxaban
Related Drugs	aspirin, propranolol, Xarelto, Eliquis, warfarin, diltiazem, digoxin, enoxaparin, apixaban, rivaroxaban
Weight	15mg, 30mg, 60mg,
Type	Tablet, Film Coated
Formula	C₂₄H₃₀ClN₇O₄S
Weight	Average: 548.06 Monoisotopic: 547.1768513
Protein binding	In vitro plasma protein binding is ~55%.
Groups	Approved
Therapeutic Class
Manufacturer	Saja-saudi Arabian Japanese Pharmaceutical Co, Daiichi Sankyo Uk Limited, Kalbe Farma
Available Country	Saudi Arabia, Canada, United Kingdom, United States, Indonesia,
Last Updated:	September 19, 2023 at 7:00 am

Uses

lixiana is a novel oral anticoagulant used for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF).

lixiana is indicated for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant.

lixiana is also used to associated treatment for these conditions: Deep Vein Thrombosis, Pulmonary Embolism, Stroke, Systemic Embolism

How lixiana works

lixiana is a selective inhibitor of factor Xa, a serine endopeptidase of the clotting cascade required for cleavage of prothrombin into thrombin.

Toxicity

Premature discontinuation of any oral anticoagulant, including edoxaban, in the absence of adequate alternative anticoagulation increases the risk of ischemic events. If edoxaban is discontinued for reasons other than pathological bleeding or completion of a course of therapy, consider the use of another anticoagulant. lixiana increases the risk of potentially fatal major bleeding such as intracranial hemorrhage and gastrointestinal bleeding. Patients should be educated on how to watch for signs of major and minor bleeding and when to seek medical help. Co-administration of other anti-coagulants, anti-platelets, or thrombolytics may increase the risk of bleeding and should therefore be avoided.

Food Interaction

Avoid herbs and supplements with anticoagulant/antiplatelet activity. Additive anticoagulant activity may increase the risk of bleeding. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
Take with or without food.

lixiana Drug Interaction

Major: dabigatranUnknown: ubiquinone, multivitamin, sacubitril / valsartan, ethanol, metformin, loperamide, metoprolol, morphine, semaglutide, acetaminophen, budesonide / formoterol, levothyroxine, tramadol, albuterol, sildenafil, cyanocobalamin, pyridoxine, ascorbic acid, cholecalciferol

lixiana Disease Interaction

Major: bleeding, hepatic impairment, valvular heart diseaseModerate: renal dysfunction

Volume of Distribution

The steady state volume of distribution is 107 L.

Elimination Route

Following oral administration, peak plasma edoxaban concentrations are observed within 1-2 hours. Absolute bioavailability is 62%.

Half Life

The terminal elimination half-life of edoxaban following oral administration is 10 to 14 hours.

Clearance

22 L/hr

Elimination Route

lixiana is eliminated primarily as unchanged drug in urine. Renal clearance (11 L/hour) accounts for approximately 50% of the total clearance of edoxaban (22 L/hour). Metabolism and biliary/intestinal excretion account for the remaining clearance.